PIRS - PIERIS PHARMACEUTICALS, INC.
IEX Last Trade
17.25
0 0%
Share volume: 0
Last Updated: Fri 13 Dec 2024 09:04:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$17.25
-2.24
0.15%
Fundamental analysis
22%
Profitability
25%
Dept financing
12%
Liquidity
49%
Performance
15%
Performance
5 Days
0 0%
1 Month
-15.05%
3 Months
-21.11%
6 Months
51.79%
1 Year
11.92%
2 Year
1,331.58%
Key data
Stock price
$17.25
DAY RANGE
$15.01 - $17.25
52 WEEK RANGE
$0.17 - $22.32
52 WEEK CHANGE
$7.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Stephen S. Yoder
Region: US
Website: pieris.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pieris.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.
Recent news